Paradoxic effects of metformin on endothelial cells and angiogenesis

Carcinogenesis

Volumn 35, Issue 5, 2014, Pages 1055-1066

  Dallaglio, Katiuscia ^a   Bruno, Antonino ^b   Cantelmo, Anna R ^b   Esposito, Alessia I ^c   Ruggiero, Luca ^b   Orecchioni, Stefania ^d   Calleri, Angelica ^d   Bertolini, Francesco ^d   Pfeffer, Ulrich ^c   Noonan, Douglas M ^b,e   Albini, Adriana ^a  

^a IRCCS   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMTS1 PROTEIN; ANGIOGENIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; CHEMOKINE RECEPTOR CXCR4; CYCLOOXYGENASE 2; CYTOCHROME P450 1B1; ENDOGLIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 8; MESSENGER RNA; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE D; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BASEMENT MEMBRANE; BREAST CANCER; CAPILLARY DENSITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID DIET; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; WHITE ADIPOSE TISSUE;

ADIPOSE TISSUE; AMP-ACTIVATED PROTEIN KINASES; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; METFORMIN; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84901978778     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu001     Document Type: Article

References (55)

1. Evans, J.M. et al. (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ, 330, 1304-1305.
2. Zhang, P. et al. (2013) Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol., 37, 207-218.
3. Ben Sahra, I. et al. (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 27, 3576-3586.
4. Phoenix, K.N. et al. (2009) Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res. Treat., 113, 101-111.
5. Akinyeke, T. et al. (2013) Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis, 34, 2823-2832.
6. Eid, A.A. et al. (2010) AMP-activated protein kinase (AMPK) negatively regulates Nox4-dependent activation of p53 and epithelial cell apoptosis in diabetes. J. Biol. Chem., 285, 37503-37512.
7. Tan, B.K. et al. (2009) Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. Cardiovasc. Res., 83, 566-574.
8. Xavier, D.O. et al. (2010) Metformin inhibits inflammatory angiogenesis in a murine sponge model. Biomed. Pharmacother., 64, 220-225.
9. Esfahanian, N. et al. (2012) Effect of metformin on the proliferation, migration, and MMP-2 and -9 expression of human umbilical vein endothelial cells. Mol. Med. Rep., 5, 1068-1074.
10. Albini, A. et al. (2012) Cancer prevention by targeting angiogenesis. Nat. Rev. Clin. Oncol., 9, 498-509.
11. Chung, A.S. et al. (2010) Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer, 10, 505-514.
12. Mann, J.R. et al. (2005) Mechanisms of disease: inflammatory mediators and cancer prevention. Nat. Clin. Pract. Oncol., 2, 202-210.
13. Albini, A. et al. (2007) The tumour microenvironment as a target for chemoprevention. Nat. Rev. Cancer, 7, 139-147.
14. Ersoy, C. et al. (2008) The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res. Clin. Pract., 81, 56-60.
15. Lund, S.S. et al. (2008) Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur. J. Endocrinol., 158, 631-641.
16. Hirsch, H.A. et al. (2013) Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc. Natl Acad. Sci. USA, 110, 972-977.
17. Caballero, A.E. et al. (2004) The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J. Clin. Endocrinol. Metab., 89, 3943-3948.
18. Abbasi, F. et al. (2004) Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism., 53, 159-164.
19. Cacicedo, J.M. et al. (2004) AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun., 324, 1204-1209.
20. De Jager, J. et al. (2005) Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J. Intern. Med., 257, 100-109.
21. Hadad, S.M. et al. (2009) Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res. Treat., 114, 391.
22. Martin, M.J. et al. (2012) Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov., 2, 344-355.
23. Cittadini, A. et al. (2012) Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes, 61, 944-953.
24. Sena, C.M. et al. (2011) Metformin restores endothelial function in aorta of diabetic rats. Br. J. Pharmacol., 163, 424-437.
25. Ziche, M. et al. (2009) Molecular regulation of tumour angiogenesis by nitric oxide. Eur. Cytokine Netw., 20, 164-170.
26. Carpentier, G. (2012) Contribution: angiogenesis analyzer. ImageJ News, 5 October 2012. http://image.bio.methods.free.fr/ImageJ/?Angiogenesis-Analyzer-for-ImageJ (21 October 2013, date last accessed).
27. Passaniti, A. et al. (1992) A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest., 67, 519-528.
28. Balwierz, A. et al. (2009) Angiogenesis in the New Zealand obese mouse model fed with high fat diet. Lipids Health Dis., 8, 13.
29. Martin-Padura, I. et al. (2012) The white adipose tissue used in lipotransfer procedures is a rich reservoir of CD34+ progenitors able to promote cancer progression. Cancer Res., 72, 325-334.
30. Mancuso, P. et al. (2011) Circulating perivascular progenitors: a target of PDGFR inhibition. Int. J. Cancer, 129, 1344-1350.
31. Dagher, Z. et al. (1999) The effect of AMP-activated protein kinase and its activator AICAR on the metabolism of human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun., 265, 112-115.
32. Ido, Y. et al. (2002) Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes, 51, 159-167.
33. Nagata, D. et al. (2003) AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J. Biol. Chem., 278, 31000-31006.
34. Ouchi, N. et al. (2004) Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J. Biol. Chem., 279, 1304-1309.
35. Shibata, R. et al. (2004) Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of AMP-activated protein kinase signaling. J. Biol. Chem., 279, 28670-28674.
36. Hattori, Y. et al. (2006) Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension, 47, 1183-1188.
37. Baud, V. et al. (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov., 8, 33-40.
38. Jalving, M. et al. (2010) Metformin: taking away the candy for cancer? Eur. J. Cancer, 46, 2369-2380.
39. Wong, C. et al. (2005) Protein kinase C-dependent protein kinase D activation modulates ERK signal pathway and endothelial cell proliferation by vascular endothelial growth factor. J. Biol. Chem., 280, 33262-33269.
40. To, K.K. et al. (2006) The phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF-2alpha in NBS1 repression. EMBO J., 25, 4784-4794.
41. Teicher, B.A. et al. (2010) CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin. Cancer Res., 16, 2927-2931.
42. Tang, Y. et al. (2010) CYP1B1 and endothelial nitric oxide synthase combine to sustain proangiogenic functions of endothelial cells under hyperoxic stress. Am. J. Physiol. Cell Physiol., 298, C665-C678.
43. Tang, Y. et al. (2009) CYP1B1 expression promotes the proangiogenic phenotype of endothelium through decreased intracellular oxidative stress and thrombospondin-2 expression. Blood, 113, 744-754.
44. Palomba, S. et al. (2013) Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and metaanalysis of randomised controlled trials. BJOG, 120, 267-276.
45. Rattan, R. et al. (2011) Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia, 13, 483-491.
46. Liao, H. et al. (2012) Luteinizing hormone facilitates angiogenesis in ovarian epithelial tumor cells and metformin inhibits the effect through the mTOR signaling pathway. Oncol. Rep., 27, 1873-1878.
47. Obika, M. et al. (2012) Tumor growth inhibitory effect of ADAMTS1 is accompanied by the inhibition of tumor angiogenesis. Cancer Sci., 103, 1889-1897.
48. Ware, W.R. (2009) Nutrition and the prevention and treatment of cancer: association of cytochrome P450 CYP1B1 with the role of fruit and fruit extracts. Integr. Cancer Ther., 8, 22-28.
49. Luby, T.M. (2008) Targeting cytochrome P450 CYP1B1 with a therapeutic cancer vaccine. Expert Rev. Vaccines, 7, 995-1003.
50. Conway, D.E. et al. (2009) Expression of CYP1A1 and CYP1B1 in human endothelial cells: regulation by fluid shear stress. Cardiovasc. Res., 81, 669-677.
51. Weis, S.M. et al. (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med., 17, 1359-1370.
52. Mikstacka, R. et al. (2007) Inhibition of human recombinant cytochromes P450 CYP1A1 and CYP1B1 by trans-resveratrol methyl ethers. Mol. Nutr. Food Res., 51, 517-524.
53. Guedez, L. et al. (2001) Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am. J. Pathol., 158, 1207-1215.
54. Gou, S. et al. (2013) Low concentrations of metformin selectively inhibit CD133+ cell proliferation in pancreatic cancer and have anticancer action. PLoS One, 8, e63969.
55. Ye, J. et al. (2013) Inflammation during obesity is not all bad: evidence from animal and human studies. Am. J. Physiol. Endocrinol. Metab., 304, E466-E477.